What We Do

Research at Deep Blue Retina

When conducting in-house clinical research, the Deep Blue Retina team analyze findings and work to develop novel therapeutics for improved patient care. In a healthcare landscape dominated by medical practices owned by either large corporate financial groups or large hospital systems, DBR brought its attention back to the two human components of the medical experience: the patient and the doctor.

The Deep Blue Retina facility and laboratory is located just outside Memphis in Southaven, MS.

The Future of Medicine

One of the stated missions of Deep Blue Retina is to be deeply involved in the future of medicine. The best way to achieve it is through collaboration with the medical technology and the biotechnology industries, where novel therapeutics are being developed. We are then able to offer our patients therapies that may help with their blinding conditions years before they are commercially available.

By participating in clinical research, patients can benefit from a new treatment that could help make vision clearer or provide better care for eye diseases.

Highest Medical Standards

Our team works with industry in clinical research protocols from early development, through phase 1, 2 and 3 of clinical trials. This not only puts our practice in the midst of forward-thinking therapeutic development.  This guarantees that our whole team, from our doctors to our technicians, are validated and certified by outside third parties to the highest levels of clinical excellence. The diagnostic and therapeutic technologies used are also validated and certified to be at the top of medical standards.

Our Current Clinical Studies

Our primary concern for all research protocols is the safety of our patients. Once you are interested in participating in a clinical trial, we will give you all of the information that you and your family need to learn about the trial.

Your very first visit will be the Screening visit. The purpose of this visit is to assess your eligibility for the study. The Informed Consent process will be conducted to ensure your comprehension about the study and your voluntary participation. In addition, there are tests that will need to be done that include but are not limited to vital signs, blood work, ophthalmic examination, and imaging. These tests will be the elements to determine your eligibility for the study. Throughout the course of the study, we will always make sure to prioritize your safety and well-being.

Diabetic Macular Edema

The ASPIRE Study (Active, Enrolling)

A prospective, multicenter, randomized, double-masked active-controlled study to assess the efficacy and safety of repeat intravitreal injections of foselutoclax (UBX1325) in patients with diabetic macular edema

This study will assess the safety and efficacy of foselutoclax (UBX1325) following repeated intravitreal injections in patients with diabetic macular edema. The medication is intended to remove certain types of aging cells from the body that no longer function properly so that healthy cells can replace the unhealthy cells lining the blood vessels. The leakage of fluid from the blood vessels would thereby be eliminated. The study lasts about nine months. 

The Photon Study (Enrollment Completed)

A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with Diabetic Macular Edema.

This study focuses on the efficacy, effectiveness, and safety of high-dose aflibercept in patients with diabetic macular edema. Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor that is administered intravitreally.

The Bardenas Study (Enrollment Completed)

A phase 2, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 in combination with ranibizumab administered intravitreally in patients with Diabetic Macular Edema.

The study aims to evaluate whether the combination of RO7200220 and ranibizumab can provide improved outcomes in terms of both efficacy and safety for patients with Diabetic Macular Edema. The combination of ranibizumab, an anti-VEGF (vascular endothelial growth factor) and RO7200220 will be administered intravitreally in one eye. The duration of the study is 18 months long.

The Alluvium Study (Enrollment Completed)

A phase 2, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with Diabetic Macular Edema.

The study's primary focus is on evaluating the efficacy of RO7200220, comparing its performance against an active comparator, ranibizumab, a standard treatment. Comprehensive assessments of safety and tolerability ensure that intravitreal administration of RO7200220 is both effective and well-tolerated by patients. This study is 18 months long.

Diabetic Retinopathy

The Canberra Study (Enrollment Completed)

A randomized, double-masked, 48-week, parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with diabetes mellitus type 1 or type 2 with treatment-naïve diabetic retinopathy.

This study investigates the efficacy and safety of RG7774, an oral medication, for patients with moderately severe to severe non-proliferative diabetic retinopathy. The 48-week duration of the study allowed a comprehensive evaluation of RG7774.  

The OTT166-201 Study (Enrollment Completed)

A phase 2 randomized, double-masked, vehicle controlled, multicenter study to evaluate the safety and efficacy of OTT166 ophthalmic solution in the treatment of diabetic retinopathy.

This study evaluates the safety and effectiveness of OTT166, an eye drop intended to treat patients with diabetic retinopathy. Patients who had moderately severe to severe non-proliferative or moderately proliferative diabetic retinopathy were enrolled. The study duration is 24 weeks long.

Geographic Atrophy

The Isis 696844-CS5 Study (Enrollment Completed)

A phase 2, randomized, placebo-controlled, double-masked study to assess safety and efficacy of multiple doses of Ionis- FB0LRX, an antisense inhibitor of complement factor B, in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration.

The study’s primary purpose was to assess both the safety and efficacy of multiple doses of Ionis-FB0LRX, an antisense inhibitor specifically targeting complement factor B. Patients who were diagnosed with Geographic Atrophy were enrolled in the study. The Ionis-FB0LRX is administered subcutaneously. This study is 57 weeks long.

The ALXN2040-GA-201 Study (Enrollment Completed)

A phase 2, double-masked, placebo-controlled, does range finding study of Danicopan (ALXN2040) in patients with geographic atrophy secondary to Age-Related Macular Degeneration.

This study intends to identify the most effective and well-tolerated dosage of Danicopan, an oral medication. Geographic atrophy, a severe form of Age-Related Macular Degeneration characterized by the progressive loss of retinal cells, has limited treatment options. Danicopan, as a complement factor D inhibitor, can be a potential treatment for patients with Geographic Atrophy. The duration of this study is 26 months.

Intermediate Age-Related Macular Degeneration

The GE43220 Study (Active, Enrolling)

A multicenter, prospective, observational study of the progression of intermediate age-related macular degeneration.

This study is dedicated to exploring the progression of intermediate age-related macular degeneration. This observational study will help and potentially guide future researchers to the treatment or prevention of age-related macular degeneration. This study is 36 months long, allowing researchers to have the most comprehensive understanding of the disease’s development.

Neovascular Age-Related Macular Degeneration

The Luna Study (Enrollment Completed)

A multi-center, randomized, double-masked phase 2 study to assess safety and efficacy of ADVM-022 (AAV.7m8-aflibercept) in anti-VEGF treatment-experienced patients with neovascular (wet) age-related macular degeneration.

This study evaluates the efficacy and safety of ADVM-022. This is a gene therapy that delivers aflibercept, a known anti-VEGF (vascular endothelial growth factor) agent. The study enrolled patients with neovascular (wet) age-related macular degeneration who also have had prior anti-VEGF treatments. This study is 13 months long.